"Designing Growth Strategies is in our DNA"

Renal Therapeutics Market Size, Share And Global Trend By Application (Chronic kidney disease, Diabetes, Kidney stone disease, Kidney failure, Others), By Drug Class (Angiotensin-II receptor blockers, ACE Inhibitors, Calcium channel blockers, Beta-blockers, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And Geography Forecast Till 2030

Region : Global | Report ID: FBI100583 | Status : Ongoing



In April 2019, Merck Sharp & Dohme Corp. received U.S Food and Drug Administration approval for the drug KEYTRUDA (pembrolizumab) for the treatment of renal cell carcinoma. According to recent studies by the National Kidney Foundation, an estimated 10% of the population globally is suffering from chronic kidney disease, and millions die annually due to lack of access to inexpensive treatment. One of the major factors leading to rise in renal disorders worldwide is the increasing prevalence of diabetes. Several novel drugs in development by key market players to treat renal disease are anticipated to fuel the global renal therapeutics market.

The global renal therapeutics market is expected to grow rapidly during the forecast period, owing to the increasing incidence & prevalence of kidney diseases and rise in the aging population. Initiatives taken by key companies in the investment of the development of the new drugs and therapies for the treatment of the renal failure combined with various pipeline drugs is estimated to lead to the growth of the global renal therapeutics market.

To gain extensive insights into the market, Request for Customization

However, the high cost of the treatment and side effects of the different treatment are some of the major restraining factors for the growth of the global renal therapeutics market.

Key Players Covered

Some of the major companies that are present in the global renal therapeutics market Amgen Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Vifor Pharma Inc., AstraZeneca, Novartis AG, Pfizer Inc., Bayer AG, and Johnson & Johnson Services, Inc. others.




By Application

·      Chronic kidney disease

·      Diabetes

·      Kidney stone disease

·      Kidney failure

·      Others

By Drug Class

·      Angiotensin-II receptor blockers

·      ACE Inhibitors

·      Calcium channel blockers

·      Beta-blockers

·      Others

By Distribution Channel

·      Hospital Pharmacies

·      Retail Pharmacies

·      Online Pharmacies

By Geography

·      North America (USA and Canada)

·      Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

·      Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

·      Latin America (Brazil, Mexico and Rest of Latin America)

·      Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)


Among the application segmentation, chronic kidney disease is anticipated to register highest market share owing to the high prevalence of this disease.

Key Insights

Overview of the prevalence of kidney diseases

Pipeline analysis

Regulatory scenario for key countries

Key mergers and acquisitions

Regional Analysis

The global renal therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to account for the largest share in the global market in 2018, owing to the rising prevalence of chronic diseases and increase in number of surgical procedures in the treatment of kidney diseases, cancer and among others. Additionally, established healthcare infrastructure in the developed countries of North America and Europe is anticipated to lead to an increase in demand for new and advanced renal therapeutics. Asia Pacific expected to register comparative higher CAGR from 2019-2026 due to rising prevalence of kidney diseases, developing healthcare infrastructure, and growing emphasis by healthcare organizations and government towards the development of new drugs, expected to drive the demand for renal therapeutics in the region from 2019-2026.

Key Industry Developments

  • In March 2019, Janssen Pharmaceuticals, Inc. submitted supplemental New Drug Application (sNDA) to the U.S FDA for canagliflozin, the first diabetic drug indicated for the treatment of chronic kidney disease in type 2 diabetic patients.  
  • In February 2019, AstraZeneca announced that the U.S FDA approved the expanded indication of dapagliflozin for treatment of moderate renal impairment.
  • In June 2018, the U.S FDA Mircera, a product manufacture by Vifor Pharma Inc. for the treatment of anaemia associated with chronic kidney disease.

  • Ongoing
  • 2021
  • 2018-2020


  • $4850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients


Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.